AURORA
Research type
Research Study
Full title
AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer
IRAS ID
162590
Contact name
Laura Stevenson
Contact email
Sponsor organisation
Breast International Group (BIG)-aisbl
Clinicaltrials.gov Identifier
Duration of Study in the UK
10 years, 0 months, 0 days
Research summary
AURORA will recruit participants with breast cancer that has either re-appeared following treatment (called "recurrent" or "local relapse" breast cancer) or spread to another part of the body (called "metastatic" breast cancer). AURORA aims to improve the understanding of recurrent/local relapse and metastatic breast cancer to improve the treatment of this disease in future. The programme will collect clinical data and test biological samples from 1,300 breast cancer patients from the UK and Europe.
Participants will be required to provide the following biological samples:
Blood samples will be collected at regular intervals:
• 1 x 10ml blood sample upon registration to participate
• 3 x 10ml blood sample (1) upon registration to participate; (2) at 6 monthly intervals; (3) if the cancer gets worse (progresses).Tissue samples will be collected for molecular testing. AURORA requires collection of a tissue sample from the primary breast tumour obtained at the time of surgery or diagnosis and a tissue sample from the recurrent/local relapse or metastatic breast cancer. The participant may have already had a biopsy of their recurrent/local relapse or metastatic breast cancer which may be suitable for the AURORA programme, if not the participant will be required to undergo an additional biopsy.
Participants will not receive any new treatments due to participation in AURORA and will continue to receive the standard treatment for their breast cancer as supervised by their doctor.
AURORA is sponsored by the Breast International Group (BIG), a non-profit organisation for academic breast cancer research groups worldwide with headquarters in Brussels, Belgium. Within the UK AURORA is coordinated by the Institute of Cancer Research Clinical Trials & Statistics Unit (ICR-CTSU).
REC name
South East Scotland REC 02
REC reference
15/SS/0084
Date of REC Opinion
23 Jun 2015
REC opinion
Further Information Favourable Opinion